Nuformix PLC Annual Report and Notice of AGM (9532X)
16 August 2018 - 4:01PM
UK Regulatory
TIDMNFX
RNS Number : 9532X
Nuformix PLC
16 August 2018
16 August 2018
Nuformix Plc
("Nuformix" or the "Company")
2018 Annual Financial Report and Notice of Annual General
Meeting
The Company announces that the following documents were posted
to its shareholders:
-- Annual Financial Report 2018
-- 2018 Notice of Annual General Meeting and Proxy Form
A full pdf version of the Annual Financial Report 2018 together
with the Notice of Annual General Meeting and sample Proxy Form are
available for download from the Document Center section on the
Company's website www.nuformix.com.
Copies of the Annual Financial Report 2018 and the Notice of
2018 Annual General Meeting and Proxy Form have been submitted to
the National Storage Mechanism and will be available for inspection
in due course at http://www.morningstar.co.uk/uk/NSM. The Nuformix
Annual Financial Report will be filed with the Registrar of
Companies in due course and copies can be obtained from the Company
Secretary, SGH Company Secretaries Limited, 60 Gracechurch Street,
London, EC3V 0HR.
The Annual General Meeting will be held on Wednesday 19
September 2018 at 1.00 pm at the offices of Shakespeare Martineau,
6(th) floor, 60 Gracechurch Street, London, EC3V 0HR.
For further information please contact:
Nuformix plc
Dan Gooding, Chief Executive Officer
+44 (0)1223 423 667
SGH Company Secretaries Ltd
Ben Harber
+44 (0)207 264 4366
Gable Communications Ltd
John Bick or Justine James
+44 (0)20 7193 7463
About Nuformix plc: www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio containing a range of
granted patents covering cocrystal forms of five small molecule
drugs. Nuformix is targeting high-value unmet needs with its lead
programmes in oncology supportive care: NXP001 and fibrosis:
NXP002.
Nuformix was established in Cambridge in 2009 and has invested
into pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities. Nuformix plc shares are
traded on the London Stock Exchange's Official List under the
ticker: NFX.L.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOASFMEFIFASESA
(END) Dow Jones Newswires
August 16, 2018 02:01 ET (06:01 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024